Noble Financial Thinks ProMIS Neurosci’s Stock is Going to Recover

By Carrie Williams

ProMIS Neurosci (PMNResearch Report) has received a rating update from a Wall Street analyst yesterday. The Healthcare company, ProMIS Neurosci (TSX: PMN) has just received a rating update from a Wall Street analyst.

According to TipRanks.com, Ordonez is ranked #4369 out of 5232 analysts.

ProMIS Neurosci has an analyst consensus of Moderate Buy, with a price target consensus of C$1.

The company has a one-year high of C$0.44 and a one-year low of C$0.18. Currently, ProMIS Neurosci has an average volume of 172.2K.

ProMIS Neurosciences, Inc. operates as a development stage biotech company. It discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis.

The company’s shares closed last Wednesday at C$0.21, close to its 52-week low of C$0.18.